SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a significant earnings beat and positive guidance, fueled by strong data center and AI-related CPU demand that has triggered a massive price rally. The community is actively debating the sustainability of this momentum, with many longs celebrating a long-awaited breakout while others caution against euphoria, drawing comparisons to past market bubbles and questioning the company's long-term profitability.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are surging in sympathy with strong earnings results from Intel, fueling renewed investor enthusiasm for the semiconductor sector as the AI infrastructure buildout continues to gain momentum. The community is actively debating the sustainability of this rapid rally, with many traders focused on the potential for a short squeeze while others express caution regarding the stock's parabolic valuation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as investors struggle with a relentless, multi-week rally in semiconductor stocks that has left the fund significantly depressed and near historic lows. The community remains heavily divided, with many debating whether this semiconductor sector strength represents an unsustainable bubble nearing a "blow-off top" or a continuation of an AI-driven supercycle that makes betting against the trend a dangerous "falling knife" scenario.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing massive volatility driven by extreme AI chip demand, a semiconductor supply "super cycle," and intense community debate over whether the surge represents a historic bubble or a persistent, momentum-driven melt-up. While bulls are riding the parabolic trend with high-leverage positions and dismissing pullbacks, skeptics are actively shorting the symbol, citing comparisons to past market manias and unsustainable valuation levels.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz is experiencing extreme volatility following a significant jury verdict awarding the company hundreds of millions in damages against a competitor, with the community actively debating whether this is the start of a massive short squeeze or a temporary pump. Investors are fixated on the potential for additional court-ordered disgorgement payments and the company's strong cash position, leading to aggressive discussion regarding the stock's future valuation and the potential for hedge funds to be caught in a massive short trap.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors debate its massive market cap against high-growth semiconductor peers like AMD and Intel, with the community closely tracking its strategic partnerships and the broader impact of AI infrastructure demand. Discussion remains polarized, with many retail traders frustrated by the stock's recent sideways movement compared to the wider chip sector, while others argue that its dominant ecosystem position makes it a long-term anchor for the AI trade.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors react to volatility driven by the company's expansion into GLP-1 treatments and broader market concerns regarding potential competition from Amazon. The community remains divided, with bullish participants pointing to strong subscriber growth and platform potential as a catalyst for a short squeeze, while bears highlight valuation concerns and the impact of the competitive landscape on margins.

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics is experiencing extreme volatility and massive trading volume following the lifting of its IPO quotation resumption halt. Investors are closely monitoring the price action as the stock establishes its initial market footing, with active community debate focused on technical support levels and the potential for sharp intraday swings typical of newly listed biotech equities.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a potential Coinbase listing and highlights its ongoing alignment with major financial infrastructure like XRP. Investors are actively debating the token's long-term utility versus its high supply, while monitoring for a breakout beyond current resistance levels.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is currently a hot topic in the crypto community following its listing on Robinhood, which has sparked significant interest regarding potential capital inflows and long-term utility. Investors are actively debating the asset's future price movements, comparing it to other privacy-focused coins, and discussing the impact of technological upgrades and regulatory developments on its market standing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.</li><li>This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers.</li><li>Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.</li></ul>Shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) soared more than 70% in Friday’s pre-market trade, a day after the company announced a direct listing on the Nasdaq stock exchange.Lakewood-Amedex Biotherapeutics began trading on the Nasdaq on Thursday, closing the day up over 8% and with a market capitalization of $122 million.<a href="https://stocktwits.com/symbol/LABT">Lakewood-Amedex Biotherapeutics shares</a> were up nearly 50% in Friday’s pre-market trade.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory, with message volumes at ‘extremely high’ levels. LABT was among the top-trending tickers on the platform at the time of writing.One user stated that the real test for LABT would be how it handles the $14 level on any pullback today would be the real test for the stock.<stembedurl>https://stocktwits.com/Olivia_Strickland/message/651253709</stembedurl><h2 class="st-heading-2">Chairman Says Listing Will Accelerate Development</h2>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers (iDFU).Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.Cooper added that of the 40 million diabetes patients in the U.S., around one-third develop DFU in their lifetime. He stated that the DFU will become infected in around half of these patients.“Numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need,” Cooper added.<h2 class="st-heading-2">Early Exploratory Trials Showed No Safety Concerns, Says Company</h2>The company stated that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns, while indicating a trend toward antimicrobial activity and improved wound healing.Based on these findings, the company plans to initiate a Phase 2a study to assess safety and dose response, followed by a placebo-controlled Phase 2b trial comparing different doses.The program will also evaluate the optimal administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers, the company said.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Lakewood-Amedex Biotherapeutics started trading on the Nasdaq on Thursday, closing the day with gains of over 8% and a market capitalization of $122 million.

LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand

Equity

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol 'LABT' Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the...

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Traders are intensely monitoring price action around the $10 to $15 zones to identify potential support bases and reversal points.

Mixed sentiment dominates as retail traders oscillate between betting on further momentum and venting about frustration with execution.

Current Price	$8.65
Prev Close	N/A
Open	$8.00
Dividend Yield	N/A
50-Day Moving Average	$8.65
Beta	0.00
Avg. Volume	0.00
PE Ratio	N/A

52-Week High	$9.82
52-Week Low	$5.75
Market Capitalization	N/A
EPS (Annual)	-$0.84
Price to Book	N/A
Revenue Per Employee	$0.00

LABT
Lakewood-Amedex Biotherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest LABT News

LABTLakewood-Amedex Biotherapeutics Inc.